Description
HLA-DR is a MHC Class II cell surface receptor heterodimer composed of a 33-35 kDa α chain, a ~30 kDa β chain, and a 10-30 amino acid ligand.{33426} When the heterodimer is fully combined on the cell surface of an antigen-presenting cell, such as macrophages, B cells, and dendritic cells, they present that ligand primarily to CD-4+ T cells.{15687} This presentation coupled with the T cell response can stimulate or suppress an antibody response to that ligand.{15687} HLR-DRs have been linked to a number of autoimmune disorders such as rheumatoid arthritis, lupus, and psoriasis as well as diabetes, hepatitis, and sclerosis among a number of others.{34485,34486,34487,34488,34489,34490,34491} Cayman’s HLA-DR Monoclonal Antibody (Clone L243) detects HLA-DR with or without attached ligand. The predicated size of the HLA-DRα or HLA-DRβ subunits is ~29-30 kDa.
Synonyms: HLA Class II Histocompatibility Antigen DR|MHC Class II Antigen DR
Immunogen: Human lymphoblastoid cell line (RPMI 8866)
Formulation: 100 µg of protein G-purified IgG
Isotype: IgG2a
Applications: FC, ICC, IF, IHC, IP, and WB
Origin:
Stability: 365 days
Application|Flow Cytometry||Application|Immunocytochemistry||Application|Immunofluorescence||Application|Immunohistochemistry||Application|Immunoprecipitation||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity|Lupus||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis